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The Increasing Importance of Systematic 
Reviews in Clinical Dermatology Research 
and Publication
The number of published systematic reviews is growing rapidly, and such reviews are receiving increased attention from sci-
entists, editors, policy makers, and consumers. 
Unlike most traditional review articles, quality 
systematic reviews use an explicit and systematic 
predefined methodology to minimize bias and 
to increase the precision of measurements of 
treatment effects. Yet methodological flaws can 
exist in systematic reviews that limit their utility. 
To reduce unnecessary duplication of clinical 
trials and ensure that scarce resources address 
the most pressing research needs, institutional 
review board panels and dermatology journals 
should consider requiring systematic reviews or 
reference to existing systematic reviews as a pre-
requisite for protocol approval and publication 
of clinical trials.
What are systematic reviews? Systematic 
reviews differ from traditional narrative expert-
opinion reviews in their comprehensive sys-
tematic approach to summarizing health-care 
evidence (Levin, 2001) and are now required 
by some biomedical journals (for example, The 
Lancet) for clinical trial publication (Young and 
Horton, 2005). The systematic approach starts 
with formulation of a clear question, followed 
by a thorough search for all relevant evidence, a 
critical appraisal of that evidence using predeter-
mined criteria, quantitative pooling (metaanaly-
sis) of similar study results when appropriate, 
and finally, interpretation of that evidence (Bigby 
et al., 2003). Authors of systematic reviews con-
ducted within the Cochrane Collaboration make 
a commitment to update the review periodically 
with the goal of fine-tuning the research in light 
of any new studies that come along. If performed 
correctly, these reviews can provide complete, 
up-to-date, and unbiased measurements of treat-
ment effectiveness by using metaanalytical sta-
tistics. High-quality systematic reviews may also 
indicate whether existing evidence is consistent 
and can be generalized across patient popula-
tions or variations in treatment (Collier et al., 
2005; Parker et al., 2004).
Why might systematic reviews be important? 
Results of isolated randomized controlled trials 
are frequently contradicted by subsequent stud-
ies (Ioannidis, 2005). Under the most rigorous 
study design conditions, a well-planned single 
study, even if prospective and randomized, 
rarely provides definitive results, and primary 
studies tend to overestimate treatment effects. 
A recent study reported that 32% of a set of 
studies with  at least 1,000 citations were either 
contradicted by or reported stronger effects 
than subsequent studies (Ioannidis, 2005). 
Relying on single high-profile clinical trials 
can therefore be harmful to patients’ health. 
Well-designed randomized controlled trials are 
excellent when looking at effectiveness, though 
many fall short in quality reporting of safety 
and adverse events associated with an inter-
vention. Quality systematic reviews often have 
increased power and decreased bias as com-
pared with the individual studies they include, 
and the careful pooling of treatment effects can 
provide the most accurate overall assessment of 
an intervention.
Benefits of systematic reviews in biomedical 
literature. Systematic reviews may save both 
lives and resources. In addition to adopt-
ing a systematic approach that minimizes 
bias, systematic reviews of all published and 
unpublished randomized controlled trials also 
have the potential through appropriate use 
of metaanalysis to produce a more precise 
estimate of treatment effect so that small but 
clinically important effects become apparent 
among a group of apparently conflicting sin-
gle trials. The human cost of failing to produce 
such systematic reviews is illustrated by the 
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life-saving potential of a systematic review conducted to 
examine infant sleeping position and sudden infant death 
syndrome. Although advice to place infants on their backs 
to sleep was widely available in the early 1990s, the authors 
of the sudden infant death syndrome study showed that the 
mortality benefit of this sleep position would have been 
apparent if a systematic review had been performed any time 
after 1970 (Gilbert et al., 2005). Such a review potentially 
could have saved 60,000 infant lives in the United Kingdom, 
Europe, the United States, and Australia.
Quality systematic reviews also possess the potential to 
save biomedical resources. Cumulative metaanalytical tech-
niques on 64 trials investigating the effectiveness of aprotinin 
showed that the effectiveness of the drug was apparent after 
only 12 trials (Fergusson et al., 2005). Thus the systematic 
review of aprotinin and perioperative bleeding identified 52 
unnecessary trials. Had a systematic review been performed 
after the twelfth study, the treatment effect would have been 
apparent, duplicate trials would have been avoided, and 
patients would have experienced the benefit of a useful drug 
ten years earlier.
Antenatal corticosteroid therapy for fetal lung matura-
tion reduces mortality, respiratory distress syndrome, and 
intraventricular hemorrhage in preterm infants (Crowley, 
2000). Although corticosteroids are routinely used today to 
accelerate fetal lung maturity in infants at risk for prema-
ture delivery, the medical community did not embrace this 
treatment unanimously during the 1970s and 1980s despite 
repeated randomized trials providing evidence supporting 
their use. A systematic review provided incontrovertible 
evidence in favor of antenatal corticosteroid therapy and 
revealed that tens of thousands of premature babies have 
needed more extensive therapy, suffered, and died unneces-
sarily (Crowley, 2000).
These are just three examples of the costs of failure to 
perform systematic, up-to-date reviews of randomized con-
trolled trials of health care in areas of medicine outside 
of dermatology. The question remains, therefore, to what 
extent such messages apply to dermatology.
Systematic reviews in dermatology
Risk of melanoma from indoor UV tanning. Systematic 
reviews may reveal clear outcomes when individual stud-
ies report widely varying, and even contrasting, results. This 
point is illustrated by a recent systematic review performed 
to examine the risk of malignant melanoma in relation to 
artificial UV radiation (Gallagher et al., 2005). Because 
exposure to artificial UV radiation through sunlamp and 
sunbed use may be intense and intermittent, concern arose 
that these devices might increase the risk of developing 
melanoma (Elwood and Jopson, 1997). Studies performed 
to identify any potential risk of developing melanoma from 
exposure to sunless tanning devices have, however, includ-
ed low numbers of exposed individuals and have reported 
inconclusive results (Elwood and Jopson, 1997). By com-
bining individual study results, Gallagher and colleagues 
(2005) were able to identify significant increased risk of 
melanoma in people exposed to artificial tanning devices.
Trials of topical immunomodulating medications and the 
“me-too” phenomenon. Systematic reviews may suppress 
the “me-too” phenomenon common in today’s industry-
driven research environment. New medications are marketed 
heavily to physicians and consumers. Trials of new pharma-
ceutical agents often fail to compare crucial active compara-
tors with the study drug. Licensing systems for medicines in 
Europe and the United States only require new drugs to show 
efficacy above placebo and vehicle, leading to a large influx 
of new medications to the market with considerable increas-
ing costs to government drug budgets (Morgan et al., 2005). 
Results from studies lacking comparison with traditional, 
often cheaper, therapies lead to confusion within the medi-
cal community regarding the efficacy of new agents. Simply 
because a newer medication is superior to a placebo does 
not mean that it is better than traditional, standard-of-care 
therapy. To examine the trials used to support the use of a 
new class of medication for the treatment of atopic derma-
titis, a systematic review combined data from randomized 
controlled trials to determine whether topical pimecrolimus 
was more effective than other treatments (Ashcroft et al., 
2005). Of 11 trials using pimecrolimus, eight compared the 
drug with vehicle only. Strikingly, none of the trials includ-
ed a comparison with what is perhaps the most appropriate 
active comparator for mild atopic dermatitis, twice-daily 1% 
hydrocortisone. Mirroring the aprotinin example, the efficacy 
of pimecrolimus as compared with vehicle at 3 weeks was 
evident after completion of three trials. Although additional 
trials are sometimes required to demonstrate efficacy in differ-
ent groups, such as adults versus children or different ethnic 
groups, and government drug administrations may require the 
repetition of clinical trials, some of the remaining trials could 
be viewed as unnecessary and a waste of research resources. 
Further studies are not needed to establish the effectiveness 
of pimecrolimus as compared with placebo.
Limitations of systematic reviews. Like all scientific research 
methodologies, systematic reviews have limitations. 
Extensive labor is involved in the creation of a quality sys-
tematic review, and the finished product can be cumbersome 
to read for those not familiar with review methodology. One 
study reported that the median length of a Cochrane system-
atic review was 15 printed pages, and a substantial number 
exceeded 30 pages (Johansen et al., 2001). Funding for these 
time-consuming systematic reviews is currently limited, and 
most are done by volunteers interested in performing them. 
Access to quality reviews is limited too, as databases of sys-
tematic reviews like the Cochrane Database are available 
online only by subscription in some countries that have not 
arranged national procurement.
The methodology associated with conducting a system-
atic review is complex, and expertise is required at each 
step, from question creation to data collection, analysis and 
interpretation. Errors can occur at any step in this complex 
process and potentially can lead to meaningless and misin-
terpreted data. Disease- and intervention-definition method-
ology used prior to the collection and analysis of data can 
greatly influence which studies are ultimately included. 
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Systematic review questions must be designed carefully so 
that the greatest number of appropriate trials is included in 
the final analysis. Therefore, quality control is essential.
A common concern expressed by those familiar with 
systematic reviews is the effect heterogeneity may have on 
review outcomes. Heterogeneity in a systematic review can 
be described as a measure of the intervention variability and 
study variation that exist among included trials. It can be dif-
ficult to know when it is appropriate to combine results from 
included trials. The decision to do so should rest on a solid 
understanding of trial heterogeneity. A critical eye is needed 
for the interpretation of the results of a systematic review, one 
that is better able to focus on the results by looking through 
sometimes complicated methodology.
To be representative of all available evidence, systematic 
reviews must be periodically updated. Updating has been 
defined as a discrete event with the aim of searching for and 
identifying new evidence to incorporate into a previously 
completed systematic review (Moher and Tsertsvadze, 2006). 
It is also often difficult to determine when it is appropriate to 
update a systematic review, as this decision must rest on an 
analysis of information evolution and the quantity of avail-
able studies.
The changing biomedical environment and systematic 
reviews. The number of systematic reviews has grown 
exponentially since 1975 (Egger et al., 2001), and a grow-
ing number of agencies are performing and using systematic 
reviews (Atkins et al., 2005). Systematic reviews now have an 
increased presence in policy at the government level, with 
reviews influencing coverage decisions made by the Centers 
for Medicare and Medicaid Services, consensus conferenc-
es, and other policy initiatives (Atkins et al., 2005; Tugwell 
et al., 2006b; Moynihan, 2004). Through the creation of an 
Equity Group, the Campbell Collaboration Equity Methods 
Group and the Cochrane Collaboration Equity Field aim to 
use systematic reviews to improve health disparities world-
wide (Tugwell et al., 2006a). Systematic reviews epitomize 
evidence-based medicine; they are regarded by some as the 
pinnacle of the evidence hierarchy (Guyatt et al., 1995) and 
are more cited than any other study design (Patsopoulos et 
al., 2005).
Weighing the pros and cons: should dermatology jour-
nals insist on systematic reviews? Using systematic reviews 
to link past to present research improves study quality and 
effectiveness and may save lives and resources, but extensive 
labor is involved in performing, publishing, and updating a 
systematic review. This extra work would especially be 
noticeable in the field of dermatology, where the numbers of 
systematic reviews published to date are few — only 3% of all 
Cochrane Reviews from a search of the Cochrane Database 
of Systematic Reviews and the Database of Abstracts of 
Reviews of Effectiveness were deemed relevant to dermatol-
ogy (Parker et al., 2004). The requirement that all new studies 
be preceded by a systematic review also creates extra work 
for the journals that must ensure this before publication of 
new information.
Given the paucity of high-quality systematic reviews in 
dermatology, insisting on systematic reviews could impart an 
extensive labor requirement on investigators and potentially 
serve as an impediment to the publication of current ongo-
ing studies. Because journal submission and peer and edi-
torial review are late steps in the publication process, more 
efficient policy might involve requiring systematic review for 
approval at the institutional review board level. Some govern-
ment bodies, such as the United Kingdom Medical Research 
Council, already insist on a systematic review or reference 
to a published one before considering funding new clinical 
trials. This requirement puts the proposed research into the 
context of the existing body of medical evidence and helps to 
avoid duplicative study.
Although systematic reviews are powerful tools, caution 
must be exercised in the consideration of policy change that 
could potentially hinder clinically useful research. Insisting 
that all new studies should be preceded by a systematic 
review may be a bit drastic for dermatology at this time. 
Insisting on the need to mention whether or not a system-
atic review has been done, and how the existing body of evi-
dence dictated the need for a new study, does seem entirely 
reasonable and achievable, however — a move that could 
discourage the nth placebo-controlled trial on another “me-
too” product.
Current publication methodology may lead to selective 
publication of results that are more favorable to study spon-
sors and to publication of trials that deviate from original 
study protocols (Al-Marzouki et al., 2005; Smith, 2005). A 
newly proposed system for reporting clinical trials would 
require the posting of a systematic review on the Internet 
as well as any subsequent study protocols related to the 
review (Smith and Roberts, 2006). This system would be 
freely accessible to patients, researchers, and editors and 
would (1) force investigators to follow the original trial 
design, thereby preventing selective publication of results 
and misleading post hoc analyses; (2) allow for feedback at 
any stage of the trial; (3) allow research teams contemplat-
ing undertaking new trials to see whether their proposed 
work has already been done; and (4) permit those report-
ing completed trials to refer to key ongoing trials. Similarly, 
more efforts need to be directed at registering all clinical tri-
als prospectively in a publicly searchable database such as 
Current Controlled Trials (http://www.controlled-trials.com) 
or the Cochrane Skin Group’s trial register (http://www.
nottingham.ac.uk/ongoingskintrials/), a free resource that 
has recently been updated to incorporate the World Health 
Organization’s latest recommendations for trials registra-
tion. The Journal of Investigative Dermatology requires reg-
istration of all clinical trials that started enrollment after July 
1, 2005 prior to publication consideration (Williams and 
Stern, 2005). The Journal of Investigative Dermatology fol-
lows International Committee of Medical Journal Editors 
standards and information regarding this policy can be 
found at the journal's website (http://www.nature.com/jid/
author_instructions.html#clinical-trials-registration).
Redundant studies waste valuable resources, including 
those of the funding body, researchers, and, most importantly, 
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patients, who usually participate in clinical studies for altru-
istic reasons. A policy at the journal or institutional review 
board level requiring any new study to relate its findings to 
the body of existing evidence should help to define the need 
for the study and sharpen its methodology. This requirement 
would help dissuade investigators from performing duplica-
tive trials to better ensure that scarce resources available for 
clinical dermatology research are targeted toward the most 
urgent research gaps.
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